MD-2 as the target of a novel small molecule, L6H21, in the attenuation of LPS-induced inflammatory response and sepsis

British Journal of Pharmacology

Volumn 172, Issue 17, 2015, Pages 4391-4405

  Wang, Yi ^a   Shan, Xiaoou ^b   Chen, Gaozhi ^a   Jiang, Lili ^b   Wang, Zhe ^a   Fang, Qilu ^a   Liu, Xing ^a   Wang, Jingying ^a   Zhang, Yali ^a   Wu, Wencan ^c   Liang, Guang ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b THE SECOND AFFILIATED HOSPITAL AND YUYING CHILDREN S HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^c EYE HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIMETHOXY 4' METHOXYCHALCONE; ARGININE; CHALCONE DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; PROTEIN MD 2; TUMOR NECROSIS FACTOR ALPHA; TYROSINE; UNCLASSIFIED DRUG; AUTACOID; CHALCONE; LIPOPOLYSACCHARIDE; LY96 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING SITE; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENCE; GENE; GENE EXPRESSION; HYDROGEN BOND; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MACROPHAGE; MACROPHAGE ACTIVATION; MD 2 GENE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; SEPSIS; SURFACE PLASMON RESONANCE; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL LINE; CHEMICALLY INDUCED; CHEMISTRY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; HUMAN; KNOCKOUT MOUSE; MALE; METABOLISM; PROCEDURES; PROTEIN SECONDARY STRUCTURE; PROTEIN TERTIARY STRUCTURE;

ANIMALS; CELL LINE; CHALCONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; LIPOPOLYSACCHARIDES; LYMPHOCYTE ANTIGEN 96; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; SEPSIS;

EID: 84938743200     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13221     Document Type: Article

References (30)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, etal. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: catalytic receptors. Br J Pharmacol 170: 1676-1705.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, etal. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: enzymes. Br J Pharmacol 170: 1797-1867.
3. Barochia A, Solomon S, Cui X, Natanson C, Eichacker PQ, (2011). Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies. Expert Opin Drug Metab Toxicol 7: 479-494.
4. Dobesh PP, Olsen KM, (2014). Statins role in the prevention and treatment of sepsis. Pharmacol Res 88C: 31-40.
5. Duan G, Zhu J, Xu J, Liu Y, (2014). Targeting myeloid differentiation 2 for treatment of sepsis. Front Biosci (Landmark Ed) 19: 904-915.
6. Esteban E, Ferrer R, Alsina L, Artigas A, (2013). Immunomodulation in sepsis: the role of endotoxin removal by polymyxin B-immobilized cartridge. Mediators Inflamm 2013: 507539.
7. Gradisar H, Keber MM, Pristovsek P, Jerala R, (2007). MD-2 as the target of curcumin in the inhibition of response to LPS. J Leukoc Biol 82: 968-974.
8. Jeon KI, Byun MS, Jue DM, (2003). Gold compound auranofin inhibits IkappaB kinase (IKK) by modifying Cys-179 of IKKbeta subunit. Exp Mol Med 35: 61-66.
9. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
10. Kim HM, Park BS, Kim JI, Kim SE, Lee J, Oh SC, etal. (2007). Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell 130: 906-917.
11. Kim SY, Koo JE, Seo YJ, Tyagi N, Jeong E, Choi J, etal. (2013). Suppression of Toll-like receptor 4 activation by caffeic acid phenethyl ester is mediated by interference of LPS binding to MD2. Br J Pharmacol 168: 1933-1945.
12. McGrath JC, Drummond GB, McLachlan EM, Kilkenny C, Wainwright CL, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
13. Mancek-Keber M, Jerala R, (2006). Structural similarity between the hydrophobic fluorescent probe and lipid A as a ligand of MD-2. FASEB J 20: 1836-1842.
14. Mancek-Keber M, Gradisar H, Inigo Pestana M, Martinez de Tejada G, Jerala R, (2009). Free thiol group of MD-2 as the target for inhibition of the lipopolysaccharide-induced cell activation. J Biol Chem 284: 19493-19500.
15. Nagai Y, Akashi S, Nagafuku M, Ogata M, Iwakura Y, Akira S, etal. (2002). Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat Immunol 3: 667-672.
16. Oblak A, Jerala R, (2015). The molecular mechanism of species-specific recognition of lipopolysaccharides by the MD-2/TLR4 receptor complex. Mol Immunol 63: 134-142.
17. Opal SM, Laterre PF, Francois B, LaRosa SP, Angus DC, Mira JP, etal. (2013). Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA 309: 1154-1162.
18. Pan Y, Zhu G, Wang Y, Cai L, Cai Y, Hu J, etal. (2013). Attenuation of high-glucose-induced inflammatory response by a novel curcumin derivative B06 contributes to its protection from diabetic pathogenic changes in rat kidney and heart. J Nutr Biochem 24: 146-155.
19. Park BS, Lee JO, (2013). Recognition of lipopolysaccharide pattern by TLR4 complexes. Exp Mol Med 45: e66.
20. Park SH, Kim ND, Jung JK, Lee CK, Han SB, Kim Y, (2012). Myeloid differentiation 2 as a therapeutic target of inflammatory disorders. Pharmacol Ther 133: 291-298.
21. Pastukhov AV, Ropson IJ, (2003). Fluorescent dyes as probes to study lipid-binding proteins. Proteins 53: 607-615.
22. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, etal.; NC-IUPHAR. (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-D1106.
23. Peluso MR, Miranda CL, Hobbs DJ, Proteau RR, Stevens JF, (2010). Xanthohumol and related prenylated flavonoids inhibit inflammatory cytokine production in LPS-activated THP-1 monocytes: structure-activity relationships and in silico binding to myeloid differentiation protein-2 (MD-2). Planta Med 76: 1536-1543.
24. Reinhart K, Gluck T, Ligtenberg J, Tschaikowsky K, Bruining A, Bakker J, etal. (2004). CD14 receptor occupancy in severe sepsis: results of a phase I clinical trial with a recombinant chimeric CD14 monoclonal antibody (IC14). Crit Care Med 32: 1100-1108.
25. Rice TW, Wheeler AP, Bernard GR, Vincent JL, Angus DC, Aikawa N, etal. (2010). A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis. Crit Care Med 38: 1685-1694.
26. Roh E, Lee HS, Kwak JA, Hong JT, Nam SY, Jung SH, etal. (2011). MD-2 as the target of nonlipid chalcone in the inhibition of endotoxin LPS-induced TLR4 activity. J Infect Dis 203: 1012-1020.
27. Tan Y, Kagan JC, (2014). A cross-disciplinary perspective on the innate immune responses to bacterial lipopolysaccharide. Mol Cell 54: 212-223.
28. Wasan KM, Sivak O, Cote RA, MacInnes AI, Boulanger KD, Lynn M, etal. (2003). Association of the endotoxin antagonist E5564 with high-density lipoproteins in vitro: dependence on low-density and triglyceride-rich lipoprotein concentrations. Antimicrob Agents Chemother 47: 2796-2803.
29. Wu J, Li J, Cai Y, Pan Y, Ye F, Zhang Y, etal. (2011). Evaluation and discovery of novel synthetic chalcone derivatives as anti-inflammatory agents. J Med Chem 54: 8110-8123.
30. Yao LH, Jiang YM, Shi J, Tomas-Barberan FA, Datta N, Singanusong R, etal. (2004). Flavonoids in food and their health benefits. Plant Foods Hum Nutr 59: 113-122.